ARS Pharmaceuticals Inc (SPRY) posted 42% year-over-year growth in neffy end-user demand and cut SG&A by over 40%, keeping it on track for cash flow breakeven by year-end 2027.
Motley Fool Press Release.
ARS Pharmaceuticals' neffy faces slow adoption and insurance hurdles but shows potential for significant market share and revenue. Read why SPRY stock is a Buy.
Detailed price information for Bank of America Corp (BAC-N) from The Globe and Mail including charting and trades.
Detailed price information for Bank of America Corp (BAC-N) from The Globe and Mail including charting and trades.
NewMediaWire Press Release.
Detailed price information for Bank of America Corp (BAC-N) from The Globe and Mail including charting and trades.
Detailed price information for Bank of America Corp (BAC-N) from The Globe and Mail including charting and trades.
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
On August 13, ARS Pharmaceuticals (NASDAQ:SPRY) held its second-quarter 2026 earnings call, the first for new President and CEO Donn Casale. He used it to lay out three priorities: sharper commercial targeting for neffy, tighter financial discipline, and a pipeline push into chronic spontaneous urticaria. The quarter itself showed a company still early in proving […]
This is the newest page. Registered accounts read further back.